Cbio T-Cell Therapy Enters the Clinic With First-in-Human Trial for Recurrent Cervical Cancer
Copenhagen-based Cbio A/S has received European regulatory clearance to initiate a first-in-human Phase I/IIa clinical trial of novoleucel, a T-cell therapy engineered to resist oxidative stress within the tumor microenvironment. The trial (EUCT 2024-517594-24) will enroll up to 20 patients with persistent or recurrent cervical cancer who have progressed after platinum-based chemotherapy and checkpoint inhibitors. Dosing will take place at Karolinska University Hospital in Stockholm, with initial safety and translational data expected by the end of 2026. Endpoints include safety, manufacturing feasibility, T-cell persistence, and early signals of clinical activity.
Novoleucel is built on research from Rolf Kiessling and Stina Wickström's group at Karolinska Institute. The therapy arms T cells through activation of the Nrf-2 pathway, a transcription factor axis that governs cellular antioxidant defenses. This modification is intended to increase resistance to reactive oxygen species that accumulate in solid tumors and suppress immune cell function. Cbio will manufacture the product at its GMP-certified facility in Copenhagen.
Research Context
The rationale for this first-in-human T-cell therapy rests on a well-characterized problem: the tumor microenvironment in solid cancers generates high levels of reactive oxygen species, which impair T-cell viability, proliferation, and cytotoxic function. Cervical tumors, driven almost universally by HPV oncoproteins E6 and E7, present defined tumor-associated antigens that make them attractive targets for adoptive cell therapy. Yet oxidative stress has remained a barrier to translating the success of cell therapies in hematologic malignancies into solid tumor settings. By activating Nrf-2, novoleucel attempts to decouple T-cell function from this immunosuppressive signal. The approach is mechanistically distinct from checkpoint blockade, which releases inhibitory braking on T cells but does not address the metabolic hostility of the tumor microenvironment itself. No AllSci hypotheses or publications specific to this molecule were available for review; this gap limits independent assessment of the preclinical evidence base supporting Nrf-2 armoring in cervical cancer models.
The treatment landscape for recurrent cervical cancer has shifted in recent years but remains constrained. Pembrolizumab gained FDA approval in combination with chemotherapy and bevacizumab for first-line PD-L1-positive recurrent or metastatic disease in 2021, and in January 2024 was approved with chemoradiotherapy for locally advanced disease based on KEYNOTE-A18. Tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, received full FDA approval in April 2024 after the Phase III innovaTV 301 trial confirmed overall survival benefit over chemotherapy. Cemiplimab was approved in 2022 as monotherapy for the second-line setting. Despite these additions, patients who progress through platinum chemotherapy and checkpoint inhibitors face median progression-free survival of roughly four months on tisotumab vedotin and considerably less on single-agent chemotherapy. No cell therapies are approved for cervical cancer. Novoleucel's target population — post-platinum, post-immunotherapy — sits in this treatment gap. Insufficient AllSci analysis was available to further characterize where current approaches fall short.